ImmunogenX

Latiglutenase is an orally administered enzyme therapy that has completed multiple Phase 2 clinical trials, most notably the CeliAction study which enrolled over 600 patients with celiac disease. The candidate is designed to be an adjunct to a gluten-free diet for patients who continue to experience symptoms. No Phase 3 initiation date has been publicly disclosed.

Latiglutenase degrades gluten in the stomach and proximal small intestine before it can trigger an immune response in the duodenum, using two recombinant gluten-specific proteases. Most other celiac disease candidates target downstream immune pathways — such as IL-15 inhibitors, transglutaminase 2 inhibitors, or tolerance-induction vaccines — rather than eliminating the antigen itself. This places the therapy in a unique mechanistic category.

The firm has engaged with the FDA on clinical endpoints for celiac disease trials, participating in the evolving discussion around patient-reported outcomes and histologic improvement as co-primary endpoints. A formal registrational pathway has not been publicly announced, but the CeliAction data has informed ongoing dialogue around what constitutes a clinically meaningful benefit in this population.

The firm has publicly explored latiglutenase as a potential treatment for irritable bowel syndrome, suggesting the candidate may have applications beyond celiac disease. Any additional pipeline assets or preclinical programs have not been publicly disclosed.

ImmunogenX has not publicly disclosed its investor syndicate, nor has it announced venture rounds by name or amount. Public records do not identify named principals or board members. The absence of this information is typical for early- to mid-stage biotech firms that have not yet entered a public registration process.

No. ImmunogenX has not filed for an initial public offering, and no ticker symbol or public listing is associated with the firm as of mid-2026. The firm operates privately.